Ghrelin and its analogues as therapeutic agents for anorexia and cachexia in end-stage renal disease.
Anorexia and cachexia are prevalent in patients with end-stage renal disease (ESRD) and are associated with increased risks of morbidity and mortality. Ashby et al. provide evidence that subcutaneous administration of synthetic ghrelin stimulated food intake in ESRD patients over a week, with no subsequent reduction in energy intake and no significant adverse effects. However, the clinical utility of ghrelin will depend on long-term outcomes in improving appetite and lean body mass as well as morbidity and mortality.
Cheung
Wai W
WW
Division of Pediatric Nephrology, Department of Pediatrics, University of California, San Diego, California 92093-0634, USA.
Mak
Robert H
RH
D000855:Anorexia / Q000188:drug therapy* / Q000209:etiology; D001066:Appetite / Q000187:drug effects; D001835:Body Weight; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D004435:Eating / Q000187:drug effects; D054439:Ghrelin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000473:pathology
D054439:Ghrelin